NASDAQHealth CareDiagnostics & ResearchSnapshot 2026-07-23
Reading XGN? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround story with a focus on improving financial performance. The current thesis state is cautious, as the company is loss-making but has stable management and a favorable sector backdrop.
The market seems to price in a low level of fragility, indicating that expectations are somewhat justified. XGN is viewed as cheap compared to its peers, but there is a significant expectations gap.
Management is on track to achieve its revenue target for 2026, but cash flow from operations shows limited progress. Recent financial performance has been weak, which could pose risks in the near term.
The long-term thesis hinges on whether XGN can maintain its revenue growth and improve cash flow. Additionally, the performance of sector bellwethers like TMO, DHR, and IDXX will be crucial in shaping market sentiment.
Over the next 1 to 3 years, XGN's outlook will depend on its ability to execute on its management priorities and the broader healthcare sector's performance. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Meeting this target would indicate strong momentum toward the full-year revenue goal of $70M to $73M.
Confirms:Q2 revenue reported at or above $17.5 million, showing continued growth.
Disproves:Q2 revenue falls below $17 million, suggesting slower growth than expected.
Why it matters: Higher operating income shows better cost control and more money coming in.
Confirms:Operating income reported better than -$3M in Q2 2026.
Disproves:Operating income reported worse than -$3M in Q2 2026.
Why it matters: If revenue growth speeds up, it could signal a positive shift in the business. This would help Exagen improve its current weak status.
Confirms:Exagen reports revenue growth above 10% year over year.
Disproves:Revenue growth remains below 10% year over year.
Why it matters: Changes in leadership can change company strategy. This can also affect performance.
Confirms one read:Management provides a clear plan to address the officer change.
Confirms the other:No updates or negative comments on the impact of the officer change.
Why it matters: New leadership can impact strategy and performance after the recent board change.
Confirms one read:Announcement of a new board member or executive.
Confirms the other:There have been no new leadership announcements for several months.
Why it matters: A smaller loss shows that costs are managed better and operations are more efficient.
Confirms:Adjusted EBITDA loss is below -$2.2 million. This means costs are better controlled.
Disproves:Adjusted EBITDA loss is still above -$2.2 million. This shows ongoing problems.
Why it matters: Sustained growth in test volume supports revenue growth and market acceptance.
Confirms:AVISE CTD test volume reported to grow by 10% or more compared to Q1.
Disproves:Test volume growth is below 5%. This suggests there may be market problems.
Why it matters: Better cash flow means the company is in better financial shape. It also shows they run their operations more efficiently.
Confirms:Cash from operations is less negative than -$10.42 million.
Disproves:Cash from operations is still more negative than -$10.42 million. This shows cash flow problems.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
